Impact of evodiamine on proliferation of human hepatocellular carcinoma HepG2 cells

ObjectiveTo study the effect and mechanism of evodiamine on proliferation of human hepatocellular carcinoma(HepG2) cells.MethodsHepG2 cells were treated with evodiamin at dosages of 5.0,12.5,25.0,50.0,and 100.0 umol/L.The cell proliferation was assayed by using 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide(MTT) method.The ability of cicatrization was analyzed with scratch wounds healing.The expressions of matrix metalloproteinase-9(MMP-9),proliferating cell nuclear antigen(PCNA) in HepG2 cells were assessed with Western blot.ResultsThe proliferation inhibition rate of evodiamine-treated groups was higher than that of the control group in a dose- and time-effect manner(P<0.05).Evodiamine could significantly inhibit cicatrization rate of HepG2 cells compared with the control group,with the cicatrization rates of 23.31±1.03%,10.37±1.06%,and 7.92±1.40% at 24 hours and 13.86±5.57%,1.78±3.08,and 0±0% at 48 hours for the groups with the dosage of 5.0,25.0,and 50.0 μmol/L,respectively(all P<0.05).The expression levels of MMP-9 and PCNA were down-regulated(0.53±0.020,0.35±0.020,and 0.21±0.015 and 0.76±0.032,0.66±0.01,and 0.59±0.015 for the groups with the dosage of 5.0,25.0,and 50.0 μmol/L)(all P<0.05).ConclusionEvodiamine can inhibit proliferation of HepG2 cells and the mechanism of the effect may be related to down-regulations of MMP-9 and PCNA proteins.